Lif - Lif's positions


	Home

	About Lif

	Media Centre

	Publications

	Lif's positions

	Cooperation agreements

Lif's Positions

Read and print Lif's positions here
Below you can read the positions section by section

Lif’s views on reimbursement
Reimbursement is a good basis for an optimal treatment of the patients. Reimbursements are granted to patients, not to the pharmaceuticals. Reimbursements are of great importance to the patients’ use of pharmaceuticals and the quality of the treatment. Lif thinks that the public reimbursements are key instruments in connection with the implementation of a healthcare policy and equal access to healthcare.

Read and print the booklet

1.0 Lif's positions - on healthcare policy

1.01 Denmark needs a healthcare policy
1.02 Remove the barrieres to advances in health technology
1.03 The principle of "No benefit, no payment"
1.04 CPD (Continuering Professional Development) for doctors is crucial
1.05 Health checks save lives
1.06 Treatment should be improved
1.07 Patients have a right to be better informed
1.08 Roles in the healthcare system

2.0 Lif's positions - on research policy

2.01 Trials must be registrered and results published
2.02 Clinical research - the foundation of future therapies
2.03 Use of non-intervention studies
2.04 Make the most of Denmark's position of strength
2.05 Improved conditions for research
2.06 Training of researchers should be developed
2.07 Basic research is short of funds

3.0 Lif's positions - on market conditions

3.01 Unit-dose dispensing should be correct used
3.02 Information about side effects is important
3.03 The doctor's prescription should be respected
3.04 Substitution of drugs
3.05 There should be no VAT on medicines
3.06 Public calls for tenders inapropiate - especially for the primary care sector
3.07 Rational pharmacotherapy should have a holistic outlook
3.08 Lif's opinion on medicine in Denmark
3.09 Dialogue on animal experiments important
3.10 Efficient regulatory data protction necessary
3.11 Efficient licensing of pharmaceutical products
3.12 Ethical agreement should be formulated
3.13 Medicines for developing countries is a complex problem
3.14 Production and quality assurance are crucial
3.15 Change of the enforcement court system
3.16 Patents are a basis for new medicinal products
3.17 Patenting stem cells and genes
3.18 Counterfeit medicines - a threat against the patient safety
3.19 Generic medicines occupy a natural place on the market

4.0 Lif's positions - on distribution of medicine

4.01 Distribution of pharmaceutical products
4.02 The pharmacy sector should be modernised on an ongoing basis
4.03 Pharmaceutical products freely traded
4.04 Flexible medicine prices
4.05 Wholesale distribution prices should be negotiable
4.06 Discounts should be abolished
4.07 Statens Serum Institut should face competition

5.0 Lif's positions - on public production

5.01 Statens Serum Institut ought to have competition
5.02 The role of hospital pharmacies should be analysed

6.0 Lif's position - On Reimbursement

6.01 Reimbursement must support and improve the optimal patient treatment
6.02 The value of pharmaceuticals for the society should always be assessed

In case of any uncertainty regarding the wording of the position (translation from Danish into English), the Danish version is the one to be used.

Print

Lif | Strødamvej 50A | 2100 København Ø | Tlf. 39 27 60 60 | Fax 39 27 60 70 | E-mail: info@lifdk.dk